Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDX Maintenance Treatment for Binge-Eating Disorder and Obesity
NCT03926052Phase 3Completed
- Sponsor
- Yale University
- Start
- Aug 2019
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in binge eating disorder (BED), sponsored by Yale University. Started Aug 2019; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT03926052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03926052.